Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 6.73
(2.28%)
CNY 6.73
(2.28%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 34.32 Million CNY | -21.88% |
| 2022 | 43.93 Million CNY | 2874.05% |
| 2021 | 1.47 Million CNY | -92.55% |
| 2020 | 19.83 Million CNY | 116.24% |
| 2019 | -122.18 Million CNY | -440.55% |
| 2018 | 35.87 Million CNY | 116.71% |
| 2017 | -214.76 Million CNY | -489.26% |
| 2016 | 55.17 Million CNY | -16.85% |
| 2015 | 66.35 Million CNY | -9.91% |
| 2014 | 73.65 Million CNY | -47.2% |
| 2013 | 139.49 Million CNY | 1743.15% |
| 2012 | 7.56 Million CNY | -62.61% |
| 2011 | 20.23 Million CNY | -19.84% |
| 2010 | 25.24 Million CNY | 67.43% |
| 2009 | 15.07 Million CNY | 9.89% |
| 2008 | 13.72 Million CNY | -43.81% |
| 2007 | 24.41 Million CNY | 10.43% |
| 2006 | 22.11 Million CNY | 43.42% |
| 2005 | 15.41 Million CNY | 456.78% |
| 2004 | 2.76 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -2.79 Million CNY | -675.51% |
| 2024 Q1 | 5.18 Million CNY | -44.95% |
| 2024 Q2 | 485.55 Thousand CNY | -90.63% |
| 2023 Q4 | 9.41 Million CNY | 41.41% |
| 2023 Q1 | 12.18 Million CNY | -43.78% |
| 2023 FY | 34.32 Million CNY | -21.88% |
| 2023 Q2 | 6.06 Million CNY | -50.25% |
| 2023 Q3 | 6.65 Million CNY | 9.81% |
| 2022 Q1 | 2.53 Million CNY | 184.04% |
| 2022 Q4 | 21.67 Million CNY | 58.63% |
| 2022 Q3 | 13.66 Million CNY | 125.52% |
| 2022 FY | 43.93 Million CNY | 2874.05% |
| 2022 Q2 | 6.05 Million CNY | 138.95% |
| 2021 Q1 | 7.76 Million CNY | -61.35% |
| 2021 Q3 | 308.76 Thousand CNY | 108.63% |
| 2021 Q4 | -3.01 Million CNY | -1077.21% |
| 2021 FY | 1.47 Million CNY | -92.55% |
| 2021 Q2 | -3.57 Million CNY | -146.09% |
| 2020 FY | 19.83 Million CNY | 116.24% |
| 2020 Q2 | -4.56 Million CNY | -372.87% |
| 2020 Q1 | 1.67 Million CNY | 101.17% |
| 2020 Q4 | 20.09 Million CNY | 660.83% |
| 2020 Q3 | 2.64 Million CNY | 157.81% |
| 2019 Q3 | 6.81 Million CNY | 25.77% |
| 2019 Q2 | 5.42 Million CNY | -36.04% |
| 2019 Q1 | 8.47 Million CNY | -55.03% |
| 2019 Q4 | -142.9 Million CNY | -2195.4% |
| 2019 FY | -122.18 Million CNY | -440.55% |
| 2018 Q3 | 5.62 Million CNY | 91.15% |
| 2018 Q1 | 8.45 Million CNY | 103.7% |
| 2018 Q2 | 2.94 Million CNY | -65.2% |
| 2018 FY | 35.87 Million CNY | 116.71% |
| 2018 Q4 | 18.85 Million CNY | 235.12% |
| 2017 Q1 | 7.83 Million CNY | -77.45% |
| 2017 FY | -214.76 Million CNY | -489.26% |
| 2017 Q4 | -228.5 Million CNY | -6041.95% |
| 2017 Q3 | 3.84 Million CNY | 86.38% |
| 2017 Q2 | 2.06 Million CNY | -73.67% |
| 2016 FY | 55.17 Million CNY | -16.85% |
| 2016 Q1 | 7.7 Million CNY | -68.89% |
| 2016 Q2 | 8.23 Million CNY | 6.79% |
| 2016 Q4 | 34.75 Million CNY | 676.69% |
| 2016 Q3 | 4.47 Million CNY | -45.65% |
| 2015 FY | 66.35 Million CNY | -9.91% |
| 2015 Q4 | 24.77 Million CNY | 154.85% |
| 2015 Q3 | 9.72 Million CNY | -45.22% |
| 2015 Q2 | 17.74 Million CNY | 25.84% |
| 2015 Q1 | 14.1 Million CNY | -38.88% |
| 2014 Q3 | 18.85 Million CNY | 23.27% |
| 2014 Q4 | 23.07 Million CNY | 22.38% |
| 2014 Q1 | 16.42 Million CNY | -86.64% |
| 2014 FY | 73.65 Million CNY | -47.2% |
| 2014 Q2 | 15.29 Million CNY | -6.87% |
| 2013 Q3 | 9.14 Million CNY | 75.84% |
| 2013 Q4 | 122.96 Million CNY | 1244.33% |
| 2013 FY | 139.49 Million CNY | 1743.15% |
| 2013 Q1 | 2.17 Million CNY | -66.84% |
| 2013 Q2 | 5.2 Million CNY | 139.31% |
| 2012 Q4 | 6.55 Million CNY | 80.73% |
| 2012 Q1 | -2.1 Million CNY | -120.31% |
| 2012 Q3 | 3.62 Million CNY | 813.45% |
| 2012 FY | 7.56 Million CNY | -62.61% |
| 2012 Q2 | -508.34 Thousand CNY | 75.85% |
| 2011 Q2 | 924.4 Thousand CNY | -87.27% |
| 2011 Q4 | 10.36 Million CNY | 513.43% |
| 2011 Q3 | 1.68 Million CNY | 82.76% |
| 2011 Q1 | 7.26 Million CNY | -40.96% |
| 2011 FY | 20.23 Million CNY | -19.84% |
| 2010 Q2 | 3.44 Million CNY | -16.97% |
| 2010 FY | 25.24 Million CNY | 67.43% |
| 2010 Q3 | 5.35 Million CNY | 55.5% |
| 2010 Q1 | 4.14 Million CNY | -18.57% |
| 2010 Q4 | 12.29 Million CNY | 129.66% |
| 2009 Q2 | 3.14 Million CNY | 18.94% |
| 2009 Q3 | 4.2 Million CNY | 33.85% |
| 2009 Q4 | 5.09 Million CNY | 21.19% |
| 2009 FY | 15.07 Million CNY | 9.89% |
| 2009 Q1 | 2.64 Million CNY | -24.14% |
| 2008 Q4 | 3.48 Million CNY | 11.07% |
| 2008 Q2 | 2.58 Million CNY | -42.88% |
| 2008 Q1 | 4.52 Million CNY | -34.75% |
| 2008 FY | 13.72 Million CNY | -43.81% |
| 2008 Q3 | 3.13 Million CNY | 21.28% |
| 2007 FY | 24.41 Million CNY | 10.43% |
| 2007 Q2 | 5.58 Million CNY | 25.47% |
| 2007 Q1 | 4.45 Million CNY | -57.42% |
| 2007 Q3 | 7.44 Million CNY | 33.36% |
| 2007 Q4 | 6.93 Million CNY | -6.93% |
| 2006 Q3 | 5.43 Million CNY | 0.0% |
| 2006 Q4 | 10.45 Million CNY | 92.27% |
| 2006 FY | 22.11 Million CNY | 43.42% |
| 2005 FY | 15.41 Million CNY | 456.78% |
| 2004 FY | 2.76 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 488.73 Million CNY | 92.978% |
| Zhejiang Zhenyuan Share Co., Ltd. | 81.64 Million CNY | 57.963% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -215.14 Million CNY | 115.952% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -140.24 Million CNY | 124.471% |
| Yifan Pharmaceutical Co., Ltd. | -551.07 Million CNY | 106.228% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 2.45 Billion CNY | 98.603% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -8.92 Million CNY | 484.44% |
| Boai NKY Medical Holdings Ltd. | 493.02 Million CNY | 93.039% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 310.18 Million CNY | 88.936% |